However, a clinical phase I dose-escalation study for treatment of multiple myeloma, non-Hodgkin lymphoma, or acute myeloid leukemia by the Mcl-1 inhibitor AMG 397 was terminated due to cardiac toxicity. This evidence concerns the gene MCL1 and AL amyloidosis.